Furthermore, these anti-tumor effects were comparable to those achieved with β-DOTA-PRIT, although with much lower levels of administered [177Lu]LuDOTA-Bn radioactivity (for GPA33: 55 MBq/mouse 19; for HER2: 167 MBq/mouse 20; for GD2: 33 MBq/mouse 17), consistent with recently reported preclinical α-therapy studies 41 including α-PRIT 52, 53. Here, GPA33 is linked to neoplasm.